About Stealth Peptides

Stealth Peptides was founded in 2006 with technologies licensed from several academic institutions. Stealth Peptides has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500-700 Daltons each) that target mitochondria. Published data for these compounds suggest significant in vitro and in vivo efficacy for cardiovascular, renal, neurologic and metabolic diseases.The intellectual property portfolio around these compounds is incredibly robust with compositions including Bendavia™ protectable by patent until 2031.

Contact Us

Stealth Peptides Incorporated
275 Grove Street, Ste. 3-107
Newton, MA 02466
(617) 600-6888
For more information about Stealth Peptides and Bendavia, please

Investor Relations

The lead investor in Stealth Peptides is Morningside Ventures. Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific and in Mainland China. Morningside was one of the earliest institutional investors in China. Its offices are located in Boston, Beijing, Shanghai and Hong Kong.